Comparative Bioavailability of Methylphenidate Powder for Prolonged-Release Oral Suspension and Methylphenidate Prolonged-Release Chewable Tablets versus Methylphenidate Immediate-Release Tablets: Phase 1, Single-Dose, Randomised, Crossover Studies in Healthy Adults

20250 citationsJournal Articlehybrid Open Access

Authors

Josep Antoni Ramos‐Quiroga · Universitat Autònoma de Barcelona

Marta Forcadell Ferré · Neuraxpharm (Spain)

Alex Schneider-Pérez · Neuraxpharm (Spain)

Mohammed Bouhajib · Pharma Medica Research (Canada)

Abstract

The methylphenidate PR oral suspension and chewable tablet formulations are bioequivalent in terms of the total extent of exposure (AUC<sub>last</sub>) to methylphenidate IR tablets and are tolerable in healthy adults.

Topics & Keywords

Attention Deficit Hyperactivity Disorder Child Nutrition and Feeding Issues Autism Spectrum Disorder Research

Publication Details

Published in: Clinical Drug Investigation

Volume 45, Issue 12, pp. 983-996

DOI: 10.1007/s40261-025-01474-3

Field-Weighted Citation Impact: 0.00

Command Palette

Comparative Bioavailability of Methylphenidate Powder for Prolonged-Release Oral Suspension and Methylphenidate Prolonged-Release Chewable Tablets versus Methylphenidate Immediate-Release Tablets: Phase 1, Single-Dose, Randomised, Crossover Studies in Healthy Adults

Authors

Abstract

Topics & Keywords

Publication Details